Dr. Pascal Behr, co-founder and CEO for 12 years, remains a member of the Board of Directors and continues to work closely as a representative on the Board to ensure continued strategic guidance. Former chief commercial officer Simon Egli has been appointed chief executive, a decision that reflects confidence in his leadership to drive the company’s next phase of growth.
This evolution in leadership position reinforces Cytosurge’s commitment to integrating operational excellence and innovation to drive advances in cell line engineering and single cell analysis to support academic and commercial research.
“On behalf of the Board of Directors, I would like to thank Pascal for his exceptional leadership and dedication over the years, and to Simon for assuming this critical role,” said Martin Gertsch, Chairman of the Board of Directors. “Under Pascal’s guidance, Cytosurge has achieved extraordinary success. Milestone: With over 140 FluidFM® systems installed worldwide, we are at the forefront of single cell research. FluidFM has been featured in over 150 scientific publications, further solidifying its influence in advancing cutting-edge research. The service was launched under Pascal’s leadership and provides high-quality genetically engineered cell lines for research, setting new standards in precision and innovation.
Simon Egli is a seasoned business leader with over ten years of experience in the life sciences industry. Prior to joining Cytosurge, Simon held senior roles at INFORS HT as Chief Commercial Officer and Global Sales Director, leading global sales operations and strategic initiatives. He also gained leadership experience as CEO of Infors USA, Inc., where he oversaw the company’s growth in the United States. Simon’s education is rooted in Switzerland, where he earned an International Executive MBA from the Rochester-Bern Executive Program and a degree in Biotechnology from ZHAW Zurich University of Applied Sciences.
Reflecting on his tenure, Dr. Pascal Behr said: “I am proud of what we have accomplished together, and I am confident that Simon, with his strategic vision and deep industry expertise, has the ability to lead Cytosurge to even greater heights.”
“I am honored to take on this role and look forward to advancing our mission of innovation in cell line engineering and single cell analysis,” added Simon Egli. “Together with our talented team, we are ready to push the boundaries of what is possible in this field.” limit.”
